Left vs right subthalamic nucleus deep brain stimulation: how it changes thinking and mood in Parkinson’s
Official title: Impact of Subthalamic Nucleus Deep Brain Stimulation on COGnitive and PSYchiatric Symptoms in Parkinson's Disease
Run by Insel Gruppe AG, University Hospital Bern · NCT07777419 · Data updated 2026-11-12
This study tests whether turning DBS on the left or the right side of the brain changes cognition and mood in people with Parkinson’s disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Insel Gruppe AG, University Hospital Bern Academic / other |
| Locations | 1 site (Bern) |
| Status | Recruiting |
| Started | August 1, 2026 |
| Main results expected | July 31, 2028 |
| Study ends | December 31, 2028 |
| Registry record updated | September 4, 2026 |
| Trial ID | NCT07777419 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with Parkinson’s disease already treated with STN-DBS, fluent in German or French, and with Montreal Cognitive Assessment score of at least 20.
✕Probably not a fit
Patients without meaningful cognitive or mood symptoms or with contraindicating conditions may not experience benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will compare how turning DBS off in the left hemisphere versus the right hemisphere affects cognitive and psychiatric symptoms in people with Parkinson’s disease who already have STN-DBS. The trial uses a crossover-like design where participants are assessed in DBS-off states for each hemisphere to see if laterality influences outcomes. The study builds on prior findings that DBS improves motor symptoms and may impact non-motor symptoms, but exact effects by stimulation side are not yet clear. Enrollment requires language fluency in German or French, and sufficient cognitive function, with clear safety exclusions for other brain conditions or severe psychiatric issues. Results could clarify whether left- or right-sided STN stimulation offers different benefits for cognition and mood.
Why it matters
Potential benefit: If successful, the findings could guide personalized DBS programming to optimize cognitive and psychiatric outcomes in PD.
How similar studies have gone: Previous DBS work shows motor benefits and possible non-motor effects, but direct side-specific cognitive/psychiatric outcomes are not yet clearly demonstrated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with Parkinson's disease * Treated with subthalamic nucleus deep brain stimulation (STN-DBS) * For part I: General research consent for the analysis of routine clinical data * For part II of the study: ability to provide informed consent * native German or French speaker * Montreal Cognitive Assessment with score ≥ 20 Exclusion Criteria: * Atypical Parkinsonism * Other disease affecting the brain (e.g. Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, non-provoked epilepsy, brain tumour, etc.) * Haemorrhage during implantation of STN-DBS, which resulted in permanent cognitive or physical impairment * Schizophrenia, ongoing substance abuse, bipolar disorder or autism * For part II: Severe depressive disorder and/or suicidality * Insufficient quality or lack of brain imaging data pre and/or post STN-DBS
Where it's running
-
University Hospital Inselspital, Berne
Bern, Switzerland Recruiting
Study contacts
- Study coordinator: Deborah Amstutz, PhD
- Email: deborah.amstutz@insel.ch
- Phone: +41 31 66 4 05 67
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Automated language analysis to help diagnose neurodegenerative diseases
A multilingual AI-powered language test is being tried to see if speech and language patterns can help differentiate Alzheimer’s, frontotemporal dementia, Lewy body dementia, and Parkinson’s from healthy aging.
-
Brain alpha-synuclein PET imaging in Parkinson's patients and healthy seniors
This open-label study tests a radioactive tracer called [18F]MK-0947 to see how it behaves in the brains of people with Parkinson's disease compared with healthy elderly volunteers.
-
Parkinson’s self-sufficiency and rehabilitation in a Czech spa setting
This intervention tests whether a Czech self-sufficiency test can be used with people with Parkinson’s disease and sees how spa-based rehabilitation affects independence, cognition, balance, and walking.
-
Imaging PD progression with [18F]AV-133 using high- and standard-resolution PET
This study tests how [18F]AV-133 PET imaging changes over 12 months in people with Parkinson's disease and a small group of healthy controls.
-
Microelectrode-based brain stimulation for Parkinson’s and essential tremor
This early feasibility test checks a new microelectrode-based brain stimulation method in adults with Parkinson’s disease or essential tremor who are already getting deep brain stimulation implants.
-
Sleep and adaptive DBS in Parkinson’s disease
This study tests whether adjusting adaptive deep brain stimulation during sleep can improve sleep quality and brain activity in people with Parkinson’s disease who already have DBS.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.